Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
AssigneeThe Regents of the University of California
InventorsR. Holland Cheng, Li Xing
Life of this patent
Estimating the term…
Abstract
This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems.
Claims18
A composition comprising:
- A capsid protein comprising a portion of HEV ORF 2 protein and a heterologous peptide, wherein the heterologous peptide is inserted into the portion of HEV ORF 2 immediately after the residue corresponding to Tyr485 of an HEV ORF 2 protein of SEQ ID NO:1, 4, 5, or 6;
- and
- a heterologous nucleic acid encapsulated in a chimeric HEV virus-like particle (VLP) formed by the capsid protein.
A composition of any one of the previous claims, further comprising a pharmaceutically acceptable excipient.
A method of inducing an immunogenic response in a host, comprising the step of administering the composition of any one of the previous claims to the host.
A capsid protein, comprising a portion of HEV ORF 2 protein and a heterologous peptide inserted into the portion of HEV ORF 2 corresponding to the portion immediately after residue Tyr485 of the HEV ORF2 of SEQ ID NO:1, 4, 5, or 6, wherein the capsid protein forms an HEV VLP.
Dependencies are inferred from the claim text.